Risk Factors for Complications and Nondiagnostic Results following 1,155 Consecutive Percutaneous Core Renal Mass Biopsies

Purpose: The purpose of this study was to evaluate patient, tumor and technical factors associated with procedural complications and nondiagnostic findings following percutaneous core renal mass biopsy. Materials and Methods: We reviewed core renal mass biopsies from 2000 to 2017. Complications at 30 days or less were graded using the Clavien-Dindo system. Univariate and multivariable analyses were done to evaluate associations between clinical characteristics and the risk of complications or nondiagnostic findings. Results: Of the 1,155 biopsies performed in a total of 965 patients procedural complications were identified in 24 patients (2.2%), including 5 (0.4%) with major complications (Clavien 3a or greater). No patients were identified with tumor seeding of the biopsy tract. Patient age, body mass index, gender, Charlson comorbidity index, smoking, mass diameter, nephrometry score, number of cores and prior biopsy were not associated with complication risk (p = 0.06 to 0.53). Complications were not increased for patients on aspirin or those with low platelets (25,000 to 160,000/&mgr;l blood) or a mildly elevated INR (international normalized ratio) (1.2 to 2.0, p = 0.16, 0.07 and 0.50, respectively). The complication risk was not increased during the initial 50 cases of a radiologist or when a trainee was present (p = 0.35 and 0.12, respectively). Nondiagnostic findings were present in 14.6% of biopsies. Independent predictors included cystic features, contrast enhancement, mass diameter and skin-to-mass distance (p <0.001, 0.002, 0.02 and 0.049, respectively). Radiologist experience was not associated with the nondiagnostic rate (p = 0.23). Prior nondiagnostic biopsy was not associated with an increased nondiagnostic rate on subsequent attempts (19.2% vs 14.2%, p = 0.23). Conclusions: Procedural complications following biopsy are rare even with low serum platelets, a mildly elevated INR or when the patient remains on aspirin. Cystic features, hypo-enhancement on imaging, a smaller mass diameter and a longer skin-to-tumor distance increase the risk of nondiagnostic findings.

[1]  B. Trock,et al.  Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study , 2018, BJU international.

[2]  Paras H Shah,et al.  The Temporal Association of Robotic Surgical Diffusion with Overtreatment of the Small Renal Mass , 2018, The Journal of urology.

[3]  A. Finelli,et al.  Is Routine Renal Tumor Biopsy Associated with Lower Rates of Benign Histology following Nephrectomy for Small Renal Masses? , 2018, The Journal of urology.

[4]  J. Cadeddu,et al.  Diagnostic Performance and Interreader Agreement of a Standardized MR Imaging Approach in the Prediction of Small Renal Mass Histology. , 2018, Radiology.

[5]  S. Windecker,et al.  Low-Dose Aspirin to Reduce the Risk for Myocardial Infarction Among Patients With Coronary Stents Undergoing Noncardiac Surgery , 2017, Annals of Internal Medicine.

[6]  S. Nakada,et al.  Comparative Analysis of Surgery, Thermal Ablation, and Active Surveillance for Renal Oncocytic Neoplasms. , 2017, Urology.

[7]  Jeffrey A. Cadeddu,et al.  Adult Urology Oncology : Adrenal / Renal / Upper Tract / Bladder lized Renal Cancer : AUA Guideline , 2017 .

[8]  P. Pierorazio,et al.  Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta‐analysis , 2017, BJU international.

[9]  A. Kutikov,et al.  Update on Renal Mass Biopsy , 2017, Current Urology Reports.

[10]  A. Evans,et al.  Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Deangelis,et al.  Bleeding Risk and Management in Interventional Procedures in Chronic Liver Disease. , 2017, Journal of vascular and interventional radiology : JVIR.

[12]  S. Wells,et al.  Renal mass biopsy and thermal ablation: should biopsy be performed before or during the ablation procedure? , 2017, Abdominal Radiology.

[13]  H. Bangash,et al.  Active surveillance is suitable for intermediate term follow‐up of renal oncocytoma diagnosed by percutaneous core biopsy , 2016, BJU international.

[14]  Kirsten Bibbins-Domingo,et al.  Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. , 2016, Annals of internal medicine.

[15]  Lorenzo Marconi,et al.  Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. , 2016, European urology.

[16]  A. Evans,et al.  Active Surveillance for Renal Neoplasms with Oncocytic Features is Safe. , 2016, The Journal of urology.

[17]  Choung-Soo Kim,et al.  Percutaneous Kidney Biopsy for a Small Renal Mass: A Critical Appraisal of Results. , 2016, The Journal of urology.

[18]  E. Bass,et al.  Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature. , 2016, The Journal of urology.

[19]  M. Blute,et al.  The evolving role of renal mass biopsy. , 2016, Annals of translational medicine.

[20]  A. Evans,et al.  Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience. , 2015, European urology.

[21]  Simon P. Kim,et al.  Increasing Biopsy Utilization for Renal Cell Carcinoma Is Closely Associated With Treatment. , 2015, Urology.

[22]  S. Nakada,et al.  Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses. , 2015, The Journal of urology.

[23]  Mark W. Ball,et al.  Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. , 2015, European urology.

[24]  M. Blute,et al.  Patient and tumor characteristics can predict nondiagnostic renal mass biopsy findings. , 2015, The Journal of urology.

[25]  M. Blute,et al.  Percutaneous biopsy for risk stratification of renal masses , 2015, Therapeutic advances in urology.

[26]  A. Gross,et al.  Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. , 2014, The Journal of urology.

[27]  J. Brooks,et al.  Utilization of renal mass biopsy in patients with renal cell carcinoma. , 2014, Urology.

[28]  R. Cohen,et al.  Percutaneous core biopsy of small renal mass lesions: a diagnostic tool to better stratify patients for surgical intervention , 2013, BJU international.

[29]  Ming Zhou,et al.  The impact of location and number of cores on the diagnostic accuracy of renal mass biopsy: an ex vivo study , 2013, World Journal of Urology.

[30]  A. Evans,et al.  Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. , 2011, European urology.

[31]  T. Winter,et al.  Coagulation concepts update. , 2009, AJR. American journal of roentgenology.

[32]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.